Previous 10 | Next 10 |
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at t...
A recent CNN report has highlighted how several athletes used psychedelics to overcome life-changing injuries and the myriad of mental-health challenges these injuries caused. Canadian Daniel Carcillo began playing professional ice hockey after graduating high school and broke into the Nation...
About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression. Another 18.1% live with anxiety disorders. And, according to Time.com, “From 20...
At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change with the US FDA’s acceptance of a New Drug Application from Lykos Therapeutics for MDMA (...
In the last couple of years, we have seen interest in psychedelics increase as more studies uncover their hidden benefits. Interest in psilocybin, the psychoactive compound found in hallucinogenic mushrooms, has increased significantly following evidence of its benefits for a range of mental-he...
2024-02-12 12:13:32 ET More on ATAI, COMPASS Pathways, etc. Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...
2024-02-06 17:11:46 ET More on ATAI Life Sciences De-Risking Psychedelics: Compass Pathways, Cybin And Atai Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value Read the full article on Seeking Alpha For further d...
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August ...
A recent influx in psychedelic-related research has revealed that some classic psychedelic drugs have the potential to offer long-term relief against several mental disorders. The expanding scientific literature states that psychedelics such as LSD, psilocybin (magic mushrooms) and ayahuasca ...
Researchers from the University of Split’s Medical School’s Department of Medical Humanities recently used computerized linguistic tools to gain insight into online reports of mystical psychedelic experiences. The scientists found that intense psychedelic experiences tend to be ...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...